Monthly prophylactic garadacimab significantly reduces hereditary angioedema attacks
1. Compared to placebo, monthly garadacimab significantly reduced the number of hereditary angioedema attacks per month. 2. Overall, garadacimab was...
Past infection with pre-omicron variants of COVID-19 protects against re-infection
1. Past infection with ancestral, alpha, beta, and delta variants of COVID-19 had a protection rate of approximately 78% against...
Secukinumab reduces symptoms of moderate-to-severe hidradenitis suppurativa
1. Patients receiving secukinumab every 2-weeks showed superior clinical response rates compared to those receiving placebo. 2. Secukinumab was well-tolerated,...
Sebetralstat improves symptom relief in acute hereditary angioedema attacks
1. An oral dose of sebetralstat increased the time to conventional treatment use and lead to faster symptom relief in...
Momelotinib reduces symptom burden compared to danazol in patients with myelofibrosis
1. After a 24-week treatment period, a significantly greater proportion of patients randomized to momelotinib had symptom scores reduced by...
Adjuvant S-1 increases short-term survival in patients with resected biliary tract cancer
1. Patients who received adjuvant S-1 had prolonged overall survival and relapse-free survival compared to those who were managed with...
Rezafungin is non-inferior to caspofungin in the treatment of candidemia and invasive candidiasis
1. Global cure was achieved in 59% of the rezafungin group compared to 61% of the caspofungin group. 2. There...
Emraclidine is safe and well-tolerated for the treatment of schizophrenia
1. Incidence of total adverse events and specific adverse events were similar between the emraclidine groups and placebo. 2. There...
Aprocitentan is an effective and safe option for the treatment of resistant hypertension
1. Compared to placebo, participants on aprocitentan had a greater reduction in office systolic blood pressure at four weeks and...
Two bedaquiline-containing regimens had superior efficacy and safety profiles for treatment of rifampin-resistant tuberculosis
1. Compared to a 9-month injectable-containing (control) regimen, both bedaquiline-containing oral regimens had more favourable outcomes, such as negative cultures....